Literature DB >> 26969325

No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.

Sonja Hutter1, Rosario M Piro2,3,4,5, Sebastian M Waszak6, Hildegard Kehrer-Sawatzki7, Reinhard E Friedrich8, Alvaro Lassaletta9, Olaf Witt3,10,11,12, Jan O Korbel6, Peter Lichter2,3, Martin U Schuhmann13,14,15, Stefan M Pfister1,3,11,12, Uri Tabori9, Victor F Mautner16, David T W Jones17,18.   

Abstract

Neurofibromatosis type 1 (NF1) is a common monogenic disorder whereby affected individuals are predisposed to developing CNS tumors, including optic pathway gliomas (OPGs, occurring in ~15 to 20 % of cases). So far, no definite genotype-phenotype correlation determining NF1 patients at risk for tumor formation has been described, although enrichment for mutations in the 5' region of the NF1 gene in OPG patients has been suggested. We used whole exome sequencing, targeted sequencing, and copy number analysis to screen 77 unrelated NF1 patients with (n = 41) or without (n = 36; age ≥10 years) optic pathway glioma for germline NF1 alterations. We identified germline NF1 mutations in 69 of 77 patients (90 %), but no genotype-phenotype correlation was observed. Our data using a larger patient cohort did not confirm the previously reported clustering of mutations in the 5' region of the NF1 gene in patients with OPG. Thus, NF1 mutation location should not currently be used as a clinical criterion to assess the risk of developing OPGs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26969325     DOI: 10.1007/s00439-016-1646-x

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  14 in total

1.  A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.

Authors:  Saba Sharif; Meena Upadhyaya; Rosalie Ferner; Elisa Majounie; Andrew Shenton; Michael Baser; Nalin Thakker; D Gareth Evans
Journal:  J Med Genet       Date:  2011-01-28       Impact factor: 6.318

2.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.

Authors:  Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson
Journal:  Genome Res       Date:  2012-02-02       Impact factor: 9.043

3.  Unified representation of genetic variants.

Authors:  Adrian Tan; Gonçalo R Abecasis; Hyun Min Kang
Journal:  Bioinformatics       Date:  2015-02-19       Impact factor: 6.937

4.  Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants.

Authors:  Sonja Hutter; Rosario M Piro; David E Reuss; Volker Hovestadt; Felix Sahm; Said Farschtschi; Hildegard Kehrer-Sawatzki; Stephan Wolf; Peter Lichter; Andreas von Deimling; Martin U Schuhmann; Stefan M Pfister; David T W Jones; Victor F Mautner
Journal:  Acta Neuropathol       Date:  2014-07-10       Impact factor: 17.088

5.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

6.  Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions.

Authors:  V-F Mautner; L Kluwe; R E Friedrich; A C Roehl; S Bammert; J Högel; H Spöri; D N Cooper; H Kehrer-Sawatzki
Journal:  J Med Genet       Date:  2010-06-12       Impact factor: 6.318

7.  Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.

Authors:  A Bolcekova; M Nemethova; A Zatkova; K Hlinkova; S Pozgayova; A Hlavata; L Kadasi; D Durovcikova; A Gerinec; K Husakova; Z Pavlovicova; M Holobrada; L Kovacs; D Ilencikova
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

8.  Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

Authors:  R Listernick; D N Louis; R J Packer; D H Gutmann
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

9.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

Authors:  L M Messiaen; T Callens; G Mortier; D Beysen; I Vandenbroucke; N Van Roy; F Speleman; A D Paepe
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

10.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

View more
  16 in total

1.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

2.  Exploring the genetic basis for clinical variation in neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Expert Rev Neurother       Date:  2016-05-30       Impact factor: 4.618

Review 3.  Germline genetic landscape of pediatric central nervous system tumors.

Authors:  Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 4.  Optic Pathway Gliomas in Neurofibromatosis Type 1.

Authors:  Cynthia J Campen; David H Gutmann
Journal:  J Child Neurol       Date:  2018-01       Impact factor: 1.987

5.  The molecular landscape of glioma in patients with Neurofibromatosis 1.

Authors:  Fulvio D'Angelo; Michele Ceccarelli; Luciano Garofano; Jing Zhang; Véronique Frattini; Francesca P Caruso; Genevieve Lewis; Kristin D Alfaro; Luc Bauchet; Giulia Berzero; David Cachia; Mario Cangiano; Laurent Capelle; John de Groot; Francesco DiMeco; François Ducray; Walid Farah; Gaetano Finocchiaro; Stéphane Goutagny; Carlos Kamiya-Matsuoka; Cinzia Lavarino; Hugues Loiseau; Véronique Lorgis; Carlo E Marras; Ian McCutcheon; Do-Hyun Nam; Susanna Ronchi; Veronica Saletti; Romuald Seizeur; John Slopis; Mariona Suñol; Fanny Vandenbos; Pascale Varlet; Dominique Vidaud; Colin Watts; Viviane Tabar; David E Reuss; Seung-Ki Kim; David Meyronet; Karima Mokhtari; Hector Salvador; Krishna P Bhat; Marica Eoli; Marc Sanson; Anna Lasorella; Antonio Iavarone
Journal:  Nat Med       Date:  2018-12-10       Impact factor: 53.440

Review 6.  Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Authors:  Juan Mo; Stefanie L Moye; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-01-23       Impact factor: 8.756

7.  Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.

Authors:  Karin Soares Cunha; Nathalia Silva Oliveira; Anna Karoline Fausto; Carolina Cruz de Souza; Audrey Gros; Thomas Bandres; Yamina Idrissi; Jean-Philippe Merlio; Rodrigo Soares de Moura Neto; Rosane Silva; Mauro Geller; David Cappellen
Journal:  Genes (Basel)       Date:  2016-12-17       Impact factor: 4.096

8.  Children with 5'-end NF1 gene mutations are more likely to have glioma.

Authors:  Corina Anastasaki; Stephanie M Morris; Feng Gao; David H Gutmann
Journal:  Neurol Genet       Date:  2017-09-22

9.  Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients.

Authors:  Donatella Bianchessi; Maria Cristina Ibba; Veronica Saletti; Stefania Blasa; Tiziana Langella; Rosina Paterra; Giulia Anna Cagnoli; Giulia Melloni; Giulietta Scuvera; Federica Natacci; Claudia Cesaretti; Gaetano Finocchiaro; Marica Eoli
Journal:  Genes (Basel)       Date:  2020-06-19       Impact factor: 4.096

10.  Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I.

Authors:  Min Xu; Hui Xiong; Yanfang Han; Chijun Li; Shaozhen Mai; Zhongzhou Huang; Xuechen Ai; Zhixuan Guo; Fanqin Zeng; Qing Guo
Journal:  Front Genet       Date:  2018-07-24       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.